At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 118 enrolled
Drug / intervention
Etrasimod +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
In Brief
A Phase 2 clinical trial evaluating Etrasimod and Placebo for Ulcerative Colitis. Completed, enrolled 118 participants across 127 sites in 21 countries.
Detailed Summary
The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesAustralia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Latvia, Lithuania, New Zealand, Poland, Romania, Russia, South Korea, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartJan 2016
Primary CompletionNov 2018
TodayJul 2026
First PostedAug 31, 2015
Enrollment StartJan 25, 2016
Primary CompletionNov 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.8 years ago
Interventions
Etrasimoddrug
Placebodrug